Novartis has submitted marketing authorization applications in the United States and Europe for the use of Femara? (letrozole) in the adjuvant (post-surgery) treatment of postmenopausal women with hormone receptor-positive early breast cancer.
Once approved for this indication, Femara will become the only breast cancer treatment available to significantly reduce the risk of recurrence in the adjuvant setting as well as in extended adjuvant treatment following tamoxifen.
“Femara represents an important advance to help increase a woman’s chance of staying cancer free after initial treatment for early breast cancer,” said Diane Young, MD, vice president and global head, Clinical Development, Novartis Oncology. “The data filed today add to the already substantial body of evidence supporting the use of Femara in breast cancer.”
- « Breast Cancer :: Anastrozole – Arimidex – New drug for breast cancer
- Breast cancer
- Breast Cancer :: Women prefer mastectomy, not lumpectomy »
Sub-editorBreast Cancer :: Femara for postmenopausal women with breast cancer
by Sub-editor ( Author at Spirit India )
Posted on July 19th, 2005 at 8:19 pm.
Find more from SpiritIndia on: Breast cancer